Atrial Fibrillation
Conditions
Brief summary
The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation with the VARIPULSE™ catheter and the TRUPULSE™ generator.
Interventions
DEVICEPulsed Field Ablation (PFA)
PFA using Irreversible Electroporation (IRE) Ablation System
Sponsors
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Symptomatic paroxysmal and persistent AF with at least one AF episode electrocardiographically documented within 24 months prior to enrollment. Electrocardiographic documentation may include, but is not limited to ECG, Transtelephonic monitoring (TTM), Zio patch monitor, telemetry strip, or consumer devices * Age 18-80 years * Willing and capable of providing written consent * Able and willing to comply with all pre-, post- and follow-up testing and requirements.
Exclusion criteria
* Previous surgical or catheter ablation for AF * Documented LA thrombus by imaging within 48 hours before procedure (CT, TEE, or intracardiac echocardiogram at the beginning of the procedure). * Uncontrolled heart failure or New York Heart Association (NYHA) Class IV * History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran) * Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study * Presence of implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device that may interfere with the PFA energy field * Women who are pregnant (as evidenced by pregnancy test if pre- menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation * Life expectancy less than 12 months * Currently enrolled in an investigational study evaluating another device, biologic, or drug that would interfere with this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of early onset primary adverse events (PAEs) | within seven (7) days of an ablation procedure |
| Freedom from documented atrial tachyarrhythmia episodes | effectiveness evaluation period (Day 91-Day 365) |
| Freedom from acute procedural failure | during ablation procedure |
Countries
United States
Outcome results
None listed